


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Compounds A compound of the general formula

I



in which

R¹ is H or A,

R², R^{2''}, R^{2'''} are each, independently of one another, H, A, OH, OCH₃, OCF₃, Hal, CN, COOR¹, CONR¹ or NO₂,

R³ is A, Ar or A-Ar,

R⁴ is H or A,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may also be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂, NR⁴SO₂A, COR⁴, SO₂N(R⁴)₂ or SO₂A,

A-Ar is arylalkyl, where A and Ar have one of the above-mentioned meanings,

Hal is F, Cl, Br or I, and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

~~and solvates, stereoisomers and pharmaceutically usable derivatives, thereof, including mixtures thereof in all ratios or a pharmaceutically acceptable salt thereof.~~

2. (Currently Amended) Compounds A compound according to Claim 1,

~~in which R¹ is hydrogen, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.~~


3. (Currently Amended) Compounds A compound according to Claim 1,
in which R^{2'}, R^{2''}, R^{2'''} are hydrogen, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.

4. (Currently Amended) Compounds A compound according to claim 1,
claim 1, in which R³ is n-propyl, i-propyl, n-butyl, 2,2,2-trifluoroethyl, phenyl, benzyl or 2-nitrophenylmethyl, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.

5. (Currently Amended) Compounds A compound according to claim 1,
in which n is 1, and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios.


6. (Currently Amended) Compounds A compound according to Claim 1,
which is selected from the group consisting of
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-phenylmethanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-C-[2-nitrophenyl]methanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]benzenesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-2-propanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-butanesulfonamide,
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-propanesulfonamide, or
N-[4-(1-benzylpiperidin-4-yloxy)phenyl]-1-2,2,2-trifluoroethanesulfonamide,
and solvates, stereoisomers and pharmaceutically usable derivatives thereof, including mixtures thereof in all ratios or a pharmaceutically acceptable salt thereof.

7. (Currently Amended) Process for the preparation of compounds of the
A process for preparing a compound of formula I according to claim 1 and pharmaceutically
usable derivatives, solvates and stereoisomers thereof, characterised in that or a
pharmaceutically acceptable salt thereof, comprising
a) reacting a compound of the formula V




V,


in which R is a nucleophilic leaving group usually employed suitable for nucleophilic substitutions substitution on an aromatic compound, is reacted compound with a compound of the formula VI



in which R^{2'}, R^{2''}, R^{2'''} and n are as defined in Claim 1 for the compound of formula I, giving a compound of the formula IV



b) the resultant phenoxy piperidine of the converting the compound of formula IV is converted by hydrogenation and optionally alkylation into a compound of the formula II



in which R¹ is as defined in Claim 1 for the compound of formula I, which is then
c) reacted further with a compound of the formula III

Error! Bookmark not defined. III,

in which R3 is as defined in Claim 1 for the compound of formula I, and L is a nucleophilic leaving group known per se, giving a compound of the formula I,
and optionally a protecting group is subsequently cleaved off,
and/or a base or acid of the a compound of formula I is converted into one of its salts.

8. (Cancelled)

9. (Cancelled)

10. (Cancelled)

11. (Currently Amended) Medicaments A pharmaceutical composition comprising at least one a compound of the formula I according to claim 1, and/or or a pharmaceutically usable derivatives, solvates and stereoisomers acceptable salt thereof, including mixtures thereof in all ratios, according to claim 1, and optionally excipients a pharmaceutically acceptable excipient and/or adjuvants adjuvant.

12. (Currently Amended) Medicaments A pharmaceutical composition according to claim 11, further comprising comprising at least one compound of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to, and at least one further medicament pharmaceutically active ingredient.

13. (Withdrawn and Currently Amended) Use of compounds according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament A method for the prophylaxis or treatment of diseases a disease in which the binding of one or more active ingredients present in the said medicament a compound of formula I according to claim 1 or a pharmaceutically acceptable salt thereof to a nicotinic and/or muscarinic acetylcholine receptor receptors leads to an improvement in the clinical picture comprising administering to a patient in need thereof an effective amount of the compound of formula I or a pharmaceutically acceptable salt thereof.

14. (Withdrawn and Currently Amended) Use of compounds according to claim 1 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety states state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative diseases disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning and or memory impairments impairment, age-related memory impairment, amelioration of withdrawal

symptoms in nicotine dependence, ~~strokes~~ stroke or brain damage by a toxic compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 11.

15. (Cancelled)

16. (Currently Amended) Process for the preparation of A process for preparing a pharmaceutical composition comprising at least one compound according to claim 1 claim 11, comprising converting said composition into a suitable dosage form together with at least one solid, liquid or semi-liquid excipient or adjuvant.

17. (Withdrawn and Currently Amended) Set (kit) consisting of A set or kit comprising separate packs of

- (a) an effective amount of a compound of the formula I according to and/or claim 1 or a pharmaceutically usable derivatives, solvates and stereoisomers acceptable salt thereof, including mixtures thereof in all ratios, and
- (b) an effective amount of a further medicament pharmaceutically active ingredient.


18. (Withdrawn and Currently Amended) Use of compounds of the formula I and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, according to claim 1, for the preparation of a medicament for the prophylaxis or treatment of schizophrenia, depression, anxiety states, dementia, Alzheimer's disease, Lewy bodies dementia, neurodegenerative diseases, Parkinson's disease, Huntington's disease, Tourette's syndrome, learning and memory impairments, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, strokes or brain damage by toxic compounds, in combination with at least one further medicament active ingredient A method for the prophylaxis or treatment of schizophrenia, depression, an anxiety state, dementia, Alzheimer's disease, Lewy bodies dementia, a neurodegenerative disease, Parkinson's disease, Huntington's disease, Tourette's syndrome, a learning or memory impairment, age-related memory impairment, amelioration of withdrawal symptoms in nicotine dependence, stroke or brain damage by a toxic compound, comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition according to claim 12.

19-20. (Cancelled)

21. (New) An isolated stereoisomer of a compound of formula I according to claim 1.

22. (New) A mixture of stereoisomers of a compound of formula I according to claim 1.

23. (New) A compound of formula I



in which

R¹ is H or A,

R^{2'}, R^{2''}, R^{2'''} are each, independently of one another, H, A, OH, OCH₃, OCF₃, Hal, CN, COOR¹, CONR¹ or NO₂,

R³ is A, Ar or A-Ar,

R⁴ is H or A,

A is unbranched or branched alkyl having 1-10 carbon atoms, in which one or two CH₂ groups may be replaced by O or S atoms and/or by -CH=CH- groups and/or 1-7 H atoms may be replaced by F,

Ar is phenyl, naphthyl or biphenyl, each of which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂, NR⁴SO₂A, COR⁴, SO₂N(R⁴)₂ or SO₂A,

A-Ar is arylalkyl, where A and Ar have one of the above-mentioned meanings,

Hal is F, Cl, Br or I, and

n is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10,

or a pharmaceutically acceptable salt or solvate thereof.

24. (New) A compound according to claim 23, wherein the solvate is a mono- or dihydrate or alcoholate.